156 related articles for article (PubMed ID: 38071684)
21. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
22. EPHA mutation as a predictor of immunotherapeutic efficacy in lung adenocarcinoma.
Bai H; Duan J; Li C; Xie W; Fang W; Xu Y; Wang G; Wan R; Sun J; Xu J; Wang X; Fei K; Zhao Z; Cai S; Zhang L; Wang J; Wang Z
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33303576
[TBL] [Abstract][Full Text] [Related]
23. Analysis on tumor immune microenvironment and construction of a prognosis model for immune-related skin cutaneous melanoma.
Wu M; Wang Z; Zhang J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 May; 48(5):671-681. PubMed ID: 37539569
[TBL] [Abstract][Full Text] [Related]
24. Gene expression and immune infiltration in melanoma patients with different mutation burden.
Wang L; Chen F; Liu R; Shi L; Zhao G; Yan Z
BMC Cancer; 2021 Apr; 21(1):379. PubMed ID: 33836680
[TBL] [Abstract][Full Text] [Related]
25. Identification of Deleterious
Zhang K; Hong X; Song Z; Xu Y; Li C; Wang G; Zhang Y; Zhao X; Zhao Z; Zhao J; Huang M; Huang D; Qi C; Gao C; Cai S; Gu F; Hu Y; Xu C; Wang W; Lou Z; Zhang Y; Liu L
Clin Cancer Res; 2020 Jul; 26(14):3649-3661. PubMed ID: 32241817
[TBL] [Abstract][Full Text] [Related]
26. Integrative lactylation and tumor microenvironment signature as prognostic and therapeutic biomarkers in skin cutaneous melanoma.
Zhu Y; Song B; Yang Z; Peng Y; Cui Z; Chen L; Song B
J Cancer Res Clin Oncol; 2023 Dec; 149(20):17897-17919. PubMed ID: 37955686
[TBL] [Abstract][Full Text] [Related]
27. Multi-omics analysis of tumor mutation burden combined with immune infiltrates in melanoma.
Jiang F; Wu C; Wang M; Wei K; Zhou G; Wang J
Clin Chim Acta; 2020 Dec; 511():306-318. PubMed ID: 33164879
[TBL] [Abstract][Full Text] [Related]
28. DNA damage repair-related gene signature predicts prognosis and indicates immune cell infiltration landscape in skin cutaneous melanoma.
Liang L; Mai S; Mai G; Chen Y; Liu L
Front Endocrinol (Lausanne); 2022; 13():882431. PubMed ID: 35957812
[TBL] [Abstract][Full Text] [Related]
29. Predicting the clinical outcome of melanoma using an immune-related gene pairs signature.
Meng L; He X; Zhang X; Zhang X; Wei Y; Wu B; Li W; Li J; Xiao Y
PLoS One; 2020; 15(10):e0240331. PubMed ID: 33031392
[TBL] [Abstract][Full Text] [Related]
30. Development of an IFNγ response-related signature for predicting the survival of cutaneous melanoma.
Hu B; Wei Q; Li X; Ju M; Wang L; Zhou C; Chen L; Li Z; Wei M; He M; Zhao L
Cancer Med; 2020 Nov; 9(21):8186-8201. PubMed ID: 32902917
[TBL] [Abstract][Full Text] [Related]
31. Identification of Prognostic Biomarkers of Cutaneous Melanoma Based on Analysis of Tumor Mutation Burden.
Lin J; Lin Y; Huang Z; Li X
Comput Math Methods Med; 2020; 2020():8836493. PubMed ID: 33273963
[TBL] [Abstract][Full Text] [Related]
32.
Ji W; Niu X; Yu Y; Li Z; Gu L; Lu S
Front Immunol; 2022; 13():955800. PubMed ID: 36405701
[TBL] [Abstract][Full Text] [Related]
33. The Association of
Wang X; Yu X; Krauthammer M; Hugo W; Duan C; Kanetsky PA; Teer JK; Thompson ZJ; Kalos D; Tsai KY; Smalley KSM; Sondak VK; Chen YA; Conejo-Garcia JR
Cancer Epidemiol Biomarkers Prev; 2020 Sep; 29(9):1792-1799. PubMed ID: 32611582
[TBL] [Abstract][Full Text] [Related]
34. ANK2 as a novel predictive biomarker for immune checkpoint inhibitors and its correlation with antitumor immunity in lung adenocarcinoma.
Zhang W; Shang X; Liu N; Ma X; Yang R; Xia H; Zhang Y; Zheng Q; Wang X; Liu Y
BMC Pulm Med; 2022 Dec; 22(1):483. PubMed ID: 36539782
[TBL] [Abstract][Full Text] [Related]
35. mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers.
Cheng L; Wang Y; Qiu L; Chang Y; Lu H; Liu C; Zhang B; Zhou Y; Bai H; Xiong L; Zhong H; Nie W; Han B
J Transl Med; 2022 May; 20(1):247. PubMed ID: 35642038
[TBL] [Abstract][Full Text] [Related]
36. Special issue "The advance of solid tumor research in China": FGFR4 alterations predict efficacy of immune checkpoint inhibitors in nonsmall cell lung cancer.
Gao G; Cui L; Zhou F; Jiang T; Wang W; Mao S; Wu F; Jiang F; Zhang B; Bei T; Xie W; Zhang C; Zhang H; Gao C; Zhao X; Bai Y; Zhou C; Ren S
Int J Cancer; 2023 Jan; 152(1):79-89. PubMed ID: 36062503
[TBL] [Abstract][Full Text] [Related]
37. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study.
Forschner A; Battke F; Hadaschik D; Schulze M; Weißgraeber S; Han CT; Kopp M; Frick M; Klumpp B; Tietze N; Amaral T; Martus P; Sinnberg T; Eigentler T; Keim U; Garbe C; Döcker D; Biskup S
J Immunother Cancer; 2019 Jul; 7(1):180. PubMed ID: 31300034
[TBL] [Abstract][Full Text] [Related]
38. Development and validation of an immune gene set-based prognostic signature in cutaneous melanoma.
Tian Q; Gao H; Zhao W; Zhou Y; Yang J
Future Oncol; 2021 Nov; 17(31):4115-4129. PubMed ID: 34291650
[TBL] [Abstract][Full Text] [Related]
39. ENPEP as a potential predictor of immune checkpoint inhibitor efficacy.
Wang A; Chu H; Jin Z; Gong Z; Jia Q; Zhu B
Cancer Med; 2022 Feb; 11(3):880-887. PubMed ID: 34862755
[TBL] [Abstract][Full Text] [Related]
40. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]